Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Patients with multiple myeloma (MM) who experience deep remissions, including minimal residual disease (MRD) negativity, have better clinical outcomes compared to those do not. We aimed to describe the effect of testing for MRD negativity in a cohort of MM patients outside of a clinical trial. For most patients, MRD negativity supports improved clinical outcomes. However, in our cohort of patients with high-risk MM, MRD negativity does not seem to affect the overall poor prognosis.

Original languageEnglish (US)
Pages (from-to)e221-e238
JournalClinical Lymphoma, Myeloma and Leukemia
Volume20
Issue number5
DOIs
StatePublished - May 2020

Keywords

  • Genetic risk
  • High-risk myeloma
  • Minimal residual disease
  • Newly diagnosed myeloma
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

MD Anderson CCSG core facilities

  • Biostatistics Resource Group

Fingerprint

Dive into the research topics of 'Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study'. Together they form a unique fingerprint.

Cite this